Condition: Colorectal Cancer Metastatic · Microsatellite Instability-High Colorectal Cancer · Sponsor: Federation Francophone de Cancerologie Digestive
The Keynote 117 phase III trial demonstrated the superiority of pembrolizumab (anti-PD1 monoclonal antibody) versus chemotherapy +/- targeted therapy in first-line treatment of dMMR/MSI metastatic colorectal cancer (mCRC). However, primary resistance to pembrolizumab was observed in approximately 20-30% of patients treated in the Keynote 177 study. Therefore, the identification of biomarkers predictive of resistance to immunotherapy for dMMR/MSI mCRC is necessary to better select patients who benefit the most from immunotherapy, and those for whom other therapeutic approaches should be favored.
This description comes directly from the study's public registry record.
Aziz ZAANAN, MD, PhD · 03 80 66 80 13 · aziz.zaanan@aphp.fr
Leathicia NDONG, MD · 0661804266 · cohorte.coresim@ffcd.fr
Always discuss trial participation with your own doctor first.
| Ch - Centre Hospitalier de La Côte Basque | Bayonne, France | Not Yet Recruiting |
| Ch - Ch Beauvais | Beauvais, France | Not Yet Recruiting |
| CH Jean Minjoz | Besançon, France | Not Yet Recruiting |
| Polyclinique Saint Privat | Boujan-sur-Libron, France | Recruiting |
| Ch - Duchenne | Boulogne-sur-Mer, France | Not Yet Recruiting |
| Ch - Centre Hospitalier Metropole Savoie | Chambéry, France | Not Yet Recruiting |
| Ch - Centre Hospitalier de Cholet | Cholet, France | Not Yet Recruiting |
| CH - Compiegne | Compiègne, France | Not Yet Recruiting |
| Ch - Chd Vendée | La Roche-sur-Yon, France | Not Yet Recruiting |
| CH - Louis Pasteur | Le Coudray, France | Not Yet Recruiting |
| Centre Hospitalier Regional et Universitaire de Lille | Lille, France | Recruiting |
| CH Saint Joseph - Saint Luc | Lyon, France | Not Yet Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06353854